Immuneering reported Q3 2026 results, extending the Phase 2 PDAC trial follow-up and expanding the Phase 3 MAPKeeper 301 enrollment target to 570 patients, which may accelerate data to mid-2028. The company also projected a cash runway into Q4 2028.
Immuneering reported Q3 2026 results, extending the Phase 2 PDAC trial follow-up and expanding the Phase 3 MAPKeeper 301 enrollment target to 570 patients, which may accelerate data to mid-2028. The company also projected a cash runway into Q4 2028.